California 2025-2026 Regular Session

California Assembly Bill AB1037

Introduced
2/20/25  
Refer
3/10/25  
Report Pass
4/9/25  
Refer
3/10/25  
Report Pass
4/9/25  
Refer
4/21/25  
Report Pass
4/24/25  
Refer
4/28/25  
Report Pass
4/30/25  
Refer
4/30/25  
Refer
5/21/25  
Report Pass
5/23/25  
Engrossed
6/5/25  
Refer
6/9/25  
Refer
6/18/25  
Report Pass
7/3/25  
Refer
7/7/25  
Report Pass
7/16/25  
Refer
7/16/25  
Refer
8/18/25  
Report Pass
8/29/25  
Enrolled
9/10/25  
Enrolled
9/10/25  
Chaptered
10/10/25  

Caption

Public health: substance use disorder.

Impact

The bill's passage is expected to significantly impact state laws surrounding drug treatment and recovery facilities. It eliminates previous mandates for abstinence and training for opioid antagonist users, thereby broadening who can respond to overdoses. The legislation emphasizes a progressive shift towards viewing substance use disorder as a health issue rather than solely a legal one, promoting harm reduction through easier access to life-saving medications. Additionally, the bill mandates that funds generated from drug program fees be allocated towards primary prevention programs based on evidence-based practices.

Summary

Assembly Bill 1037, introduced by Elhawary, addresses public health issues related to substance use disorders. The bill amends several sections in the Civil and Health and Safety Codes, primarily focusing on expanding the management and distribution of opioid antagonists, like naloxone, to combat opioid overdoses. It allows individuals in positions to assist a person experiencing an overdose to possess and administer opioid antagonists without the requirement for prior training, aiming to increase accessibility and save lives during emergencies.

Sentiment

The sentiment around AB 1037 appears to be largely positive among proponents who view it as an essential update to the state's approach towards public health and overdose prevention. Advocates argue that making opioid antagonists more accessible saves lives and reflects a compassionate understanding of addiction as a health issue. However, there may be some contention from critics who believe that reduced training and oversight could lead to improper usage or dilute the quality of care in recovery settings.

Contention

A notable point of contention lies in the bill's removal of the requirement for individuals possessing or administering opioid antagonists to undergo training. Critics question whether this could hinder effective use during real-life emergency situations. Furthermore, amendments affecting treatment facilities and licensing processes may raise concerns regarding the potential for inconsistent care standards in drug recovery programs, as facilities may not require patients to be abstinent upon admission.

Companion Bills

No companion bills found.

Previously Filed As

CA SB43

Substance use disorder: addiction treatment referral agencies.

CA HB06838

An Act Concerning Access To Substance Use Disorder Treatment Facilities.

CA SB1280

Health care coverage for mental health and substance use disorders.

CA SB00195

An Act Concerning The Prevention Of Accidental Overdose Deaths And Improving Access To Treatment And Recovery Services For Substance Use Disorder.

CA SCR15

Substance Use Disorder Treatment Month.

CA SB00476

An Act Declaring Opioid And Substance Use Disorders A Public Health Crisis And Establishing A Commission On Opioid And Substance Use Disorders.

CA AB1970

Health care coverage: mental health or substance use disorders.

CA S0432

Intoxicating Substances

CA SB1814

Substance use disorder treatment; committee

CA H0309

Controlled Substances

Similar Bills

AZ HB2697

Expired opioid antagonists; use

CA AB1586

Opioid overdose reversal medication: school resource officers.

CO SB066

State Contracts with Opioid Antagonist Businesses

CO SB164

Opioid Antagonist Availability & State Board of Health

CT HB05515

An Act Concerning The Department Of Mental Health And Addiction Services' Recommendations Regarding Access To Opioid Overdose Reversal Medication And Various Revisions To Mental Health And Addiction Statutes.

CT HB07179

An Act Concerning Pharmaceutical Marketing And Pharmaceuticals.